The Washington Post reports: An experimental Alzheimer’s drug slowed cognitive and functional decline by 27 percent in a closely watched clinical trial, the sponsors of the medication said Tuesday, increasing the therapy’s chance for approval as soon as early next year. Japanese drugmaker Eisai and its American partner, Biogen, in a news release said the slowing of deterioration, compared with …
Read More »